Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 11, 2009, Pages 1549-1557

  Guarneri, Valentina ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Advanced breast cancer; HER2 positive; Hormone receptor positive; Lapatinib; Letrozole; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBAMAZEPINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXEMESTANE; GEFITINIB; HORMONE RECEPTOR; IMATINIB; KETOCONAZOLE; LAPATINIB; LETROZOLE; LOPERAMIDE; PLACEBO; SORAFENIB; STEROID; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ANOREXIA; AREA UNDER THE CURVE; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; HEAD AND NECK CANCER; HEART DISEASE; HEPATOBILIARY DISEASE; HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; NAUSEA; POSTMENOPAUSE; REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRIAZOLES;

EID: 71949087792     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.124     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
3. Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784-1792 (2005).
4. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85-94 (2001).
5. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255-6263 (2002).
6. Zhou H, Kim YS, Peletier A et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2- overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys. 58, 344-352 (2004). (Pubitemid 38142458)
7. Konecny G, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006). (Pubitemid 43259947)
8. Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65, 18-25 (2005). (Pubitemid 40070791)
9. Xia W, Liu LH, Ho P et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23, 646-653 (2004). (Pubitemid 38241266)
10. Bence AK, Anderson EB, Doukas MA et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs 23, 39-49 (2005).
11. Pandite L, Burris H, Jones L et al. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J. Clin. Oncol. 22(14 Suppl.), (2004) (Abstract 3179).
12. Smith DA, Koch KM, Lee D et al. The effect of food on the pharmacokinetic of GW572016. Eur. J. Cancer 169(Suppl. 1), (2003) (Abstract 558).
13. Koch KM, Reddy NJ, Cohen RB et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J. Clin. Oncol. 27, 1191-1196 (2009).
14. Versola M, Burris HA, Jones S et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 23, (2004) (Abstract 3047).
15. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305-5313 (2005). • Phase I study describing the safety, pharmacokinetics and activity of lapatinib in 67 heavily pretreated patients with solid tumors and advanced disease. Lapatinib was well tolerated at doses from 500 to 1600 mg once daily, and interesting levels of activity were also observed.
16. Nakagawa K, Minami H, Kanezaki M et al. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. Jpn. J. Clin. Oncol. 39, 116-123 (2009).
17. Blackwell KL, Pegram MD, Tan-Chiu E et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20, 1026-1031 (2009).
18. Burstein HJ, Storniolo AM, Franco S et al. A Phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 19, 1068-1074 (2008). (Pubitemid 351796331)
19. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999-3005 (2008).
20. Johnston S, Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 26, 1066-1072 (2008).
21. Kaufman B, Trudeau M, Awada A et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a Phase II study. Lancet Oncol. 10, 581-588 (2009). •• Phase II trial of lapatinib monotherapy in 126 patients with relapsed or refractory HER2-positive inflammatory breast cancer. A partial response was observed in 39% of the patients, with a median duration of response of 20.9 weeks. Lapatinib monotherapy has shown interesting levels of activity in this particularly aggressive form of breast cancer.
22. Cristofanilli M, Boussen H, Baselga J et al. A Phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Presented at: 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, USA 14-17 December 2006 (Abstract 1).
23. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993-1999 (2008).
24. Lin NU, Diéras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009). • Describes the activity of lapatinib in 242 patients with CNS metastases, previously treated with trastuzumab and cranial irradiation. In this particularly difficult-to-treat disease, lapatinib monotherapy was associated with a volumetric brain lesion reduction in 21% of the patients. Additional responses were observed in an expanded cohort receiving capecitabine and lapatinib following progression of lapatinib monotherapy.
25. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85-95 (1992)
26. Pietras R, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene 10, 2435-2446 (1995)
27. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 65, 118-121. (1992)
28. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23, 1616-1622 (2005). •• This very interesting review offers a detailed description of the biology of the estrogen receptor and discusses related therapeutic implications. (Pubitemid 46211414)
29. Kushner PJ, Agard DA, Greene GL et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317 (2000).
30. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 7, 4429s-4435s (2001). (Pubitemid 34031592)
31. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclise and cAMP-regulated gene transcription. Proc. Natl Acad. Sci. USA 91, 8517-8521(1994).
32. Chu QS, Cianfrocca ME, Goldstein LJ et al. A Phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin. Cancer Res. 14, 4484-4490 (2008).
33. Johnston S, Pegram M, Press M et al. Lapatinib combined with letrozole vs letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. Presented at: 31st Annual San Antonio Breast Cancer Symposium San Antonio, TX, USA 10-14 December 2008 (Abstract 46).
34. Sherif BN, Sherrill B, Amonkar M et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer (MBC): a quality-of-life (QOL) analysis. J. Clin. Oncol. 27(15S), (2009) (Abstract 1039).
35. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM Study. J. Clin. Oncol. (2009) (Epub ahead of print).
36. Frassoldati A, Guarneri V, Piacentini F et al. Letrozole versus letrozole plus Lapatinib (GW572016) in hormonesensitive, HER2-negative operable breast cancer: a double-blind, randomized, Phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin. Breast Cancer 8, 97-100 (2008). (Pubitemid 351346237)
37. Frassoldati A, Guarneri V, Bottini A et al. Preplanned first-step analysis of LET-LOB neoadjuvant study: a double-blind randomized Phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer. J. Clin. Oncol. 27(15), (2009) (Abstract 570).
38. Crown JP, Burris HA 3rd, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 112, 317-325 (2008). •• This pooled analysis summarized diarrhea events across nine studies enrolling more than 2000 patients.
39. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 114, 485-493 (2009). •• This pooled analysis summarized the skin toxicity in more than 2000 patients enrolled in nine lapatinib clinical trials.
40. Moy B, Sorensen PG, Tange UB et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J. Clin. Oncol. 27(15S), (2009) (Abstract 1043).
41. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008). •• This is a pooled analysis of cardiac events in 3689 patients enrolled in 44 clinical trials, showing low levels of cardiotoxicity for lapatinib. (Pubitemid 351810568)
42. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J. Clin. Oncol. 24, 4107-4115 (2006). (Pubitemid 46622286)
43. Zembryki D, Byrne J, Gomez H et al. Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol. 27(15S), (2009) (Abstract 1095).
44. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res. Treat. 117(3), 577-589 (2009).